MedTrace Logo

A Study of Parenterally-administered Teverelix TFA in Healthy Male Volunteers

NCT03781947 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2020-03-17

No results posted yet for this study

Summary

A Phase I, open-label, single centre study investigating the pharmacokinetics, safety and pharmacodynamics of a single dose of teverelix TFA, a gonadotrophin releasing hormone antagonist, via subcutaneous or intramuscular route of administration in healthy male volunteers

Conditions

  • Healthy

Interventions

DRUG

teverelix TFA

A single s.c. or i.m. injection of teverelix TFA administered on Day 1

Sponsors & Collaborators

  • Antev Ltd.

    lead INDUSTRY

Principal Investigators

  • Pablo Forte Soto, MD · Parexel

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-11-19
Primary Completion
2020-03-16
Completion
2020-03-16

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03781947 on ClinicalTrials.gov